Drug Trial Radar · NCT06990529
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Apr 29, 2025
Primary completion
Aug 12, 2029
Study completion Aug 12, 2029
Sponsor
- Lead sponsor
- Pharming Technologies B.V.Industry
- Sponsor type
- Industry
- Collaborators
- Aixial Group
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension (OLE) study to extend treatment to patients with primary immunodeficiency (PID) disorders linked to phosphoinositide 3-kinase delta signaling who participated in a prior study of leniolisib, LE 7201. The primary objective is to assess long-term safety and tolerability of leniolisib. Secondary and exploratory objectives include various efficacy and immunophenotyping measures for leniolisib.
Conditions
- PIDs Linked to PI3K
Interventions
LeniolisibDrug
All subjects will receive leniolisib film-coated tablets (FCTs) at the same dose they were receiving when they completed the preceding study (10, 30, or 70 mg twice daily \[BID\]).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the long-term safety and tolerability of leniolisibTime frame: From Baseline to approximately 3 years of Treatment
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
National Institute of Health
Bethesda, Maryland
Lahey Hospital & Medical Center
Burlington, Massachusetts
Mount Sinai Hospital
New York, New York
IIS La Fe
Valencia, Spain
St James Hospital
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.